Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Inhibikase Therapeutics, Inc. (IKT) had Return on Equity of -12.78% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-19.59M |
|
-- |
|
-- |
|
$21.05M |
|
$-21.05M |
|
$1.46M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-21.05M |
|
$-21.05M |
|
174.57M |
|
174.57M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$162.34M |
|
-- |
|
$1.24M |
|
$163.59M |
|
$10.26M |
|
-- |
|
-- |
|
$10.26M |
|
$153.33M |
|
$153.33M |
|
$153.33M |
|
132.03M |
|
| Cash Flow Statement Financials | |
$-24.50M |
|
$-86.39M |
|
$2.88M |
|
$139.22M |
|
$31.21M |
|
$-108.01M |
|
$10.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-12.78% |
-12.78% |
|
-11.98% |
|
-12.78% |
|
$1.16 |
|
$-0.14 |
|
$-0.14 |
|